Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors.

In our previous study [ 20 ], supportive therapy (antiemetics, erythropoietins, colony-stimulating growth factors, and hypocalcemia medications) accounted for 4.6% of the total pharmaceutical expenditure for the treatment of solid tumors in patients treated in the routine healthcare setting, and although this percentage is low, it showed a decreasing trend along the years, with only 1.4% in 2019.

also in 47,180 other papers